ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 914,65
-0,88%
Dow Jones
38 166,40
0,69%
DAX
17 896,50
-0,14%
Brent Oil
83,57
0,04%
Bitcoin
59 131,09
1,53%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Avalo Therapeutics Inc (AVTX)

  7. Avalo Therapeutics Inc (AVTX) Actualités

AVTX Avalo Therapeutics Inc

16,3499
0,3499 (2,19%)
Dernière mise à jour : 21:30:31
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Avalo Therapeutics Inc AVTX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,3499 2,19% 16,3499 21:30:31
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
16,20 16,146 17,42 16,00
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
02/4/202413:00GLOBEAvalo Therapeutics Appoints Biotech Leaders to Board of..
29/3/202421:01GLOBEAvalo Reports 2023 Financial Results and Provides Business..
27/3/202421:01GLOBEAvalo Acquires Anti-IL-1β mAb and Announces Private..
15/2/202403:13EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202416:02EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
31/1/202422:01EDGAR2Form 8-K - Current report
28/12/202323:05EDGAR2Form 8-K - Current report
27/12/202313:00GLOBEAvalo Therapeutics Announces 1-for-240 Reverse Stock Split
21/12/202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/12/202322:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202322:01EDGAR2Form 8-K - Current report
07/12/202313:02EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
07/12/202313:01EDGAR2Form 8-K - Current report
07/12/202313:00GLOBEAvalo Encourages Stockholders to Vote FOR the Reverse Stock..
16/11/202313:15EDGAR2Form 8-K - Current report
09/11/202313:21EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202313:04EDGAR2Form 8-K - Current report
09/11/202313:00GLOBEAvalo Reports Third Quarter 2023 Financial Results and..
31/10/202312:21EDGAR2Form 8-K - Current report
31/10/202312:00GLOBEAvalo Completes Divestiture of AVTX-800 Series
19/10/202322:15EDGAR2Form ARS - Annual Report to Security Holders
19/10/202322:06EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
19/10/202322:01EDGAR2Form DEF 14A - Other definitive proxy statements
17/10/202322:02EDGAR2Form 8-K - Current report
05/10/202322:02EDGAR2Form PRE 14A - Other preliminary proxy statements
26/9/202313:04EDGAR2Form 8-K - Current report
26/9/202313:00GLOBEAvalo Therapeutics Successfully Eliminates $35 Million Debt..
13/9/202322:03EDGAR2Form 8-K - Current report
13/9/202315:12EDGAR2Form 8-K - Current report
12/9/202313:10EDGAR2Form 8-K - Current report
12/9/202313:00GLOBEAvalo Enters into Agreement to Divest AVTX-800 Series
11/9/202313:22EDGAR2Form 8-K - Current report
06/9/202313:00GLOBEAvalo to Present at the H.C. Wainwright 25th Annual Global..
14/8/202322:23EDGAR2Form 8-K - Current report
08/8/202322:11EDGAR2Form 8-K - Current report
07/8/202323:27EDGAR2Form 8-K - Current report
07/8/202323:26EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
03/8/202313:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202313:01EDGAR2Form 8-K - Current report
03/8/202313:00GLOBEAvalo Reports Second Quarter 2023 Financial Results and..
21/7/202314:25EDGAR2Form 8-K - Current report
06/7/202322:01GLOBEAvalo to Participate in SVB Securities Therapeutics Forum
29/6/202314:22EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
29/6/202300:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/6/202313:00GLOBEAvalo Announces Topline Data from Phase 2 PEAK Trial for..
01/6/202313:00GLOBEAvalo to Present at the Jefferies Healthcare Conference
22/5/202313:00GLOBEAvalo Announces Appointment of Michael Croft, Ph.D. and Jeff..
15/5/202313:00GLOBEAvalo to Present at ATS 2023 Respiratory Innovation Summit
10/5/202313:00GLOBEAvalo to Present at the 2023 RBC Capital Markets Global..
04/5/202322:01GLOBEAvalo Reports First Quarter 2023 Financial Results and..

Dernières Valeurs Consultées

NASDAQ
AVTX
Avalo Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés